| Initiation of antiretroviral therapy in early asymptomatic HIV infection. JD Lundgren, AG Babiker, F Gordin, S Emery, B Grund, S Sharma, ... The New England journal of medicine 373 (9), 795-807, 2015 | 2157 | 2015 |
| Initiation of antiretroviral therapy in early asymptomatic HIV infection Insight Start Study Group New England Journal of Medicine 373 (9), 795-807, 2015 | 1135 | 2015 |
| HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects M J Buzón, M Massanella, JM Llibre, A Esteve, V Dahl, MC Puertas, ... Nature medicine 16 (4), 460-465, 2010 | 654 | 2010 |
| Dolutegravir in antiretroviral-experienced patients with raltegravir-and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study A Castagna, F Maggiolo, G Penco, D Wright, A Mills, R Grossberg, ... The Journal of infectious diseases 210 (3), 354-362, 2014 | 415 | 2014 |
| Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 … JM Llibre, CC Hung, C Brinson, F Castelli, PM Girard, LP Kahl, EA Blair, ... The Lancet 391 (10123), 839-849, 2018 | 397 | 2018 |
| Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection E Martínez, JA Arnaiz, D Podzamczer, D Dalmau, E Ribera, P Domingo, ... New England Journal of Medicine 349 (11), 1036-1046, 2003 | 388 | 2003 |
| Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study E Martinez, M Larrousse, JM Llibre, F Gutierrez, M Saumoy, A Antela, ... Aids 24 (11), 1697-1707, 2010 | 240 | 2010 |
| Characteristics, comorbidities, and outcomes in a multicenter registry of patients with human immunodeficiency virus and coronavirus disease 2019 D Dandachi, G Geiger, MW Montgomery, S Karmen-Tuohy, M Golzy, ... Clinical Infectious Diseases 73 (7), e1964-e1972, 2021 | 215 | 2021 |
| A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study) D Podzamczer, E Ferrer, E Consiglio, JM Gatell, P Perez, JL Perez, ... Antiviral therapy 7 (2), 81-90, 2002 | 197 | 2002 |
| Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study D Podzamczer, E Ferrer, P Sanchez, JM Gatell, M Crespo, C Fisac, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 44 (2), 139-147, 2007 | 181 | 2007 |
| Sexual transmission of hepatitis C virus and its relation with hepatitis B virus and HIV. J Tor, JM Llibre, M Carbonell, R Muga, A Ribera, V Soriano, B Clotet, ... British Medical Journal 301 (6761), 1130-1133, 1990 | 170 | 1990 |
| Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study JM Llibre, MJ Buzón, M Massanella, A Esteve, V Dahl, MC Puertas, ... Antiviral therapy 17 (2), 355-364, 2012 | 143 | 2012 |
| Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir E Martínez, MD Polyana, JM Llibre, F Gutierrez, D Podzamczer, A Antela, ... Aids 26 (18), 2315-2326, 2012 | 135 | 2012 |
| Genetic barrier to resistance for dolutegravir. JM Llibre, F Pulido, F García, M Garcia Deltoro, JL Blanco, R Delgado AIDS reviews 17 (1), 2015 | 130 | 2015 |
| Lymphogranuloma venereum proctocolitis: a silent endemic disease in men who have sex with men in industrialised countries R Martin-Iguacel, JM Llibre, H Nielsen, E Heras, L Matas, R Lugo, B Clotet, ... European journal of clinical microbiology & infectious diseases 29, 917-925, 2010 | 130 | 2010 |
| The lipid-lowering effect of tenofovir/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial JR Santos, M Saumoy, A Curran, I Bravo, JM Llibre, J Navarro, C Estany, ... Clinical Infectious Diseases 61 (3), 403-408, 2015 | 122 | 2015 |
| Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study J Mallolas, D Podzamczer, A Milinkovic, P Domingo, B Clotet, E Ribera, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 51 (1), 29-36, 2009 | 119 | 2009 |
| A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected … E Martínez, JA Arranz, D Podzamczer, M Loncá, J Sanz, P Barragán, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 51 (3), 290-297, 2009 | 114 | 2009 |
| Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir JM Llibre, P Domingo, R Palacios, J Santos, MJ Pérez-Elías, ... Aids 20 (10), 1407-1414, 2006 | 109 | 2006 |
| Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients L Ruiz, R Paredes, G Gómez, J Romeu, P Domingo, N Pérez-Alvarez, ... Aids 21 (2), 169-178, 2007 | 107 | 2007 |
